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A B S T R A C T
Background: Rivaroxaban is currently used to prevent stroke in patients with atrial ﬁbrillation.
Measuring coagulation function may help clinicians to understand the effects of this drug and the
associated risk of bleeding.
Methods and results: Rivaroxaban was given to 136 patients with non-valvular atrial ﬁbrillation. Mean
age was 74.5  9.0 years (men: 63.2%) and mean CHADS2 score (SD) was 1.8  1.2. Prothrombin times
(PTs) and plasma soluble ﬁbrin (SF) levels were examined in 84 out of 136 patients at baseline and at least
2 weeks thereafter. In 48 patients we were able to collect blood at exact times, namely just before and 3 h
after rivaroxaban administration, corresponding to the trough and peak concentrations. Mean peak PT in
48 patients was 17.1  3.6 s and median peak SF level was 1.46 mg/mL. Multiple regression analysis showed
that female sex, high brain natriuretic peptide, and high dose were independent factors prolonging the peak
PT. Patients with peak PTs 20 s experienced signiﬁcantly more bleeding events. Among 29 of 46 patients
newly treated with rivaroxaban without any previous anticoagulant, we examined coagulation function at
the exact trough and peak times. In 29 patients, peak PT was signiﬁcantly more prolonged than the baseline
or trough PT (p < 0.001 for both), whereas trough PT was comparable to the baseline PT. In contrast, both
trough and peak SF levels in these newly treated patients were signiﬁcantly reduced than at baseline
(p = 0.003 and p < 0.001, respectively).
Conclusions: In Japanese patients with non-valvular atrial ﬁbrillation receiving rivaroxaban, a prolonged
peak PT (20 s) could indicate increased risk of bleeding, and both trough and peak SF levels were
reduced relative to baseline. PT and SF are both valuable measures of coagulation status in patients
receiving rivaroxaban, regardless of prior anticoagulant history.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Anticoagulation therapy is mandatory for preventing stroke in
patients with atrial ﬁbrillation (AF) [1–3]. The numbers of patients
with AF are increasing, making anticoagulation therapy all the more
necessary [4–6]. Over the past 50 years, warfarin has been used in
oral anticoagulation therapy, but there are several problems
associated with its use. For example, administration of warfarin* Corresponding author at: Department of Advanced Medicine in Cardiopulmo-
nary Disease, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho,
Shouwa-ku, Nagoya 466-8560, Japan. Tel.: +81 52 744 0388; fax: +81 52 744 0388.
E-mail address: takahisa@med.nagoya-u.ac.jp (T. Kondo).
http://dx.doi.org/10.1016/j.jjcc.2014.07.021
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsrequires: (1) a ﬁxed period to become effective; (2) adequate patient
education for proper compliance; and (3) regular monitoring of the
prothrombin time (PT) – international normalized ratio to maintain
drug safety and efﬁcacy [7–9].
Recently, novel oral anticoagulants (NOACs) have been proven to
be non-inferior to warfarin in terms of preventing ischemic stroke,
and they may be superior with respect to the risk of major bleeding
[10–13]. Moreover, NOACs do not require frequent monitoring of
their anticoagulation effects. However, these ﬁndings were obtained
in large-scale clinical trials and are applicable only to the types of
patients who met the inclusion criteria for each trial. In an actual
clinical setting, patients with heart failure or poor medication
adherence also need to be treated with anticoagulants. Furthermore,
coagulation function must be measured in many other instances, reserved.
Y. Nakano et al. / Journal of Cardiology 65 (2015) 185–190186such as in patients on anticoagulants undergoing emergency surgery
or exhibiting hemorrhage.
Rivaroxaban was the second NOAC to be approved worldwide
after dabigatran [10,14]. Data on coagulation function in patients
treated with rivaroxaban are limited [15–18], and only Yama-
shita’s group have reported the distribution of PT in Japanese AF
patients treated with rivaroxaban [19]. Here, we measured PTs to
determine the safety proﬁle of rivaroxaban; we chose PT because it
is the most widely used coagulation test. In addition, we measured
plasma levels of soluble ﬁbrin (SF), which is generated from
thrombin–ﬁbrinogen reactions and is a potentially useful marker
of hypercoagulability [20–22].
Materials and methods
Study design and participants
This observational study of Japanese patients with non-valvular
AF treated with rivaroxaban was conducted in routine clinical
practice at Tosei General Hospital, Aichi, Japan. From 1 May 2012 to
31 May 2013, a total of 136 patients began treatment with
rivaroxaban and were considered for study entry. Coagulation
function was examined in 84 of these patients at baseline and at least
2 weeks later. In 48 of these 84 patients, we were able to collect blood
accurately at times corresponding to the trough and peak
concentrations of rivaroxaban. Patients gave written informed
consent to participate, and the study was conducted in accordance
with the ethical policy of Tosei General Hospital. We also performed
outcome and safety evaluations in all 136 patients treated with
rivaroxaban. The observation period lasted till 31 December 2013.
Dose of rivaroxaban
Patients received oral rivaroxaban at a dose of either 15 mg once
daily (O.D.) or 10 mg O.D. Patients took rivaroxaban after breakfast,
and their adherence to medication was monitored. Each dose was
determined by the attending physician on the basis of the creatinine
clearance (CCr), determined with the Cockcroft–Gault formula, i.e.
men, [(140  age)/(serum creatinine)]  (weight/72); women, 0.85
[(140  age)/(serum creatinine)]  (weight/72)], or of the presence of
a previous history of bleeding complications or concurrent use of
antiplatelet drugs, or both. Patients were allocated to three groups:
patients who received 15 mg O.D. and had CCr  50 mL/min; those
who received 10 mg O.D. and had CCr < 50 mL/min; and those who
received 10 mg O.D. and had CCr  50 mL/min.
Measuring coagulation function
PTs and SF levels were examined at baseline (before the start of
rivaroxaban treatment) and at trough and peak times at least
2 weeks after the start of treatment. We deﬁned the trough time as
immediately before the administration of rivaroxaban and the
peak time as 3 h after drug administration. Therefore, patients
brought the drug with them and then took it orally at the hospital
after the ﬁrst blood collection in the morning. Blood was collected
again 3 h later. PT was determined with the recombinant human
tissue factor-based thromboplastin reagent (HemosIL Recombi-
PlasTin, Instrumentation Laboratory, Lexington, MA, USA). SF was
quantiﬁed by latex photometric immunoassay (IATRO SF II, LSI
Medience Corporation, Tokyo, Japan).
Outcomes
Outcomes were deﬁned in accordance with the ROCKET AF
study and J-ROCKET AF study [10,14]. Outcome events included
stroke or any other form of embolism in a major organ. In the safetyevaluation we counted major and non-major clinically relevant
bleeding events. A major bleeding event was deﬁned as clinically
overt bleeding associated with a decrease in hemoglobin level of
20 g/L, transfusion of 2 units of packed red blood cells or whole
blood, involvement of an intracranial site, or a fatal outcome. A
non-major clinically relevant bleeding event was deﬁned as
clinically overt bleeding that did not meet the criteria for major
bleeding but that required medical intervention or resulted in the
impairment of daily activities.
Statistical analysis
Categorical variables are presented as numbers and percentages
(%). Continuous variables are presented as means  standard
deviation or medians. Pearson’s correlation was used to measure the
strength of the relationship between two variables. To compare PTs
between groups we used the unpaired t-test, paired t-test, chi-square
test, or one-way ANOVA. To compare SF levels between groups we used
the Wilcoxon signed-rank test or Kruskal–Wallis test. We performed
stepwise multiple regression analysis to evaluate the factors affecting
peak PT. A p-value < 0.05 was considered statistically signiﬁcant. All
statistical analyses were conducted with the SPSS statistical software
program (SPSS version 18.0 for Windows, SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Patient characteristics are shown in Table 1. Mean age of all
patients (n = 136) was 74.5 years, and 63.2% were men. Eighty-ﬁve
patients suffered from paroxysmal AF and 51 suffered from
persistent or long-standing persistent AF. CCr < 50 mL/min was
observed in 30.2% of all patients. During the study, 15.4% of all
patients were taking antiplatelet drugs concurrently.
Prothrombin time
The mean trough and peak PTs in the 48-patient group were
11.1  1.0 s and 17.1  3.6 s, respectively (Fig. 1a). Peak PTs were
distributed normally and were more signiﬁcantly prolonged than
trough PTs (p < 0.001); the trough PTs were comparable to the
normal value used in our hospital laboratory (10.9  0.9 s). PTs were
compared among the three groups, namely 15 mg O.D. with
CCr  50 mL/min, 10 mg O.D. with CCr < 50 mL/min, and 10 mg
O.D. with CCr  50 mL/min. Baseline PTs were widely distributed
within all three groups (12.7  4.2 s, 11.4  1.9 s, and 13.0  2.6 s,
respectively) and depended on prior anticoagulant therapy. Trough
PTs were comparable among the three groups (11.0  1.0 s,
11.1  0.8 s, and 11.2  1.4 s, respectively; p = 0.850) (Fig. 1b) and
were not signiﬁcantly prolonged in each group compared with the
normal values used in our hospital laboratory (data not shown). Peak
PTs did not differ signiﬁcantly among the three groups (17.7  3.4 s,
16.7  3.7 s, and 16.9  3.8 s, respectively; p = 0.725) (Fig. 1c).
In the 48-patient group, there was no correlation overall between
peak PT and CCr (r = 0.012, p = 0.933; Fig. 2). Moreover, there was
no correlation between peak PT and CCr in any of the three groups
[15 mg O.D. with CCr  50 mL/min (r = 0.01, p = 0.972), 10 mg O.D.
with CCr < 50 mL/min (r = 0.31, p = 0.196), 10 mg O.D. with
CCr  50 mL/min (r = 0.173, p = 0.553)]. B-type natriuretic peptide
(BNP) was negatively correlated with CCr (r = 0.416, p < 0.001).
We also performed a stepwise multiple regression analysis to
evaluate the factors affecting peak PT (Table 2). Female sex, high
BNP, and high dose were signiﬁcantly related to peak PT, whereas
CCr was not. There were no differences in CCr between male and
female patients (males: 63.9 mL/min; females: 63.8 mL/min,
p = 0.987). Female patients tended to exhibit more prolonged peak
PT PT
 
ba c
PT
p = 0.850 p = 0.725
p < 0.001
(s) (s) (s)
Fig. 1. (a) Distributions of prothrombin time (PT) at trough and peak. Mean values at trough and peak PT were 11.1  1.0 s and 17.1  3.6 s, respectively. (b and c) Trough and
peak PTs in each group according to CCr and dose. PT, prothrombin time; O.D., once daily; CCr, creatinine clearance. Horizontal lines in boxes represent medians. Tops and bottoms of
boxes indicate 75th and 25th percentile, respectively. Tops and bottoms of bars indicate maximum and minimum non-outliers, respectively. Circles indicate outliers above or below
1.5 times the interquartile range from the 75th to the 25th percentile.
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even though more males than females were receiving the higher
dose (15 mg O.D.) (p = 0.007) and the CCr was comparable between
the sexes.Table 1
Characteristics of the patients.
Overall
(n = 136)
Patients examined
for coagulation
function (n = 84)
Age (years) 74.5  9.0 76.0  8.5
Age 75 years, n (%) 70 (51.5) 49 (58.3)
Sex, n (%)
Male 86 (63.2) 52 (61.9)
Female 50 (36.8) 32 (38.1)
Body mass index 23.4  4.1 23.1  4.2
Body weight (kg) 59.4  11.9 58.4  12.3
Daily dose (mg O.D.) 12.1  2.5 11.8  2.4
10 mg O.D., n (%) 78 (57.4) 53 (63.1)
15 mg O.D., n (%) 58 (42.6) 31 (36.9)
Previous anticoagulants
None, n (%) 81 (59.6) 46 (54.8)
Warfarin, n (%) 32 (23.5) 22 (26.2)
Dabigatran, n (%) 13 (9.6) 9 (10.7)
Unfractionated heparin, n (%) 10 (7.4) 7 (8.3)
Concurrent antiplatelet drugs
Aspirin, n (%) 8 (5.9) 5 (6.0)
Clopidogrel, n (%) 1 (0.7) 1 (1.2)
Cilostazol, n (%) 2 (1.5) 1 (1.2)
Aspirin + clopidogrel, n (%) 9 (6.6) 7 (8.3)
Aspirin + cilostazol, n (%) 1 (0.7) 0 (0)
CHADS2 score
Mean 1.8  1.2 1.9  1.1
0, n (%) 19 (14.0) 9 (10.7)
1, n (%) 38 (27.9) 22 (26.2)
2, n (%) 41 (30.1) 33 (39.3)
3, n (%) 38 (27.9) 20 (23.8)
Congestive heart failure, n (%) 36 (26.5) 24 (28.6)
Hypertension, n (%) 93 (68.4) 60 (71.4)
Diabetes mellitus, n (%) 22 (16.2) 11 (13.1)
Baseline stroke/systemic embolism, n (%) 14 (10.3) 6 (7.1)
Baseline creatinine clearance
Mean (mL/min) 66.5  27.9 63.8  27.6
15–29 mL/min, n (%) 10 (7.4) 7 (8.3)
30–<50 mL/min, n (%) 31 (22.8) 19 (22.6)
50–<80 mL/min, n (%) 55 (40.4) 39 (46.4)
80 mL/min, n (%) 40 (29.4) 19 (22.6)
Dose and creatinine clearance
15 mg O.D., CCr 50 mL/min 58 (42.6) 31 (36.9)
10 mg O.D., CCr <50 mL/min 39 (28.7) 25 (29.8)
10 mg O.D., CCr 50 mL/min 39 (28.7) 28 (33.3)
O.D., once daily; CCr, creatinine clearance.Outcome assessment
Outcomes were assessed in a total of 136 patients treated with
rivaroxaban. One embolism event was observed. This patient was
an 82-year-old male whose CCr was 53.6 mL/min and who was
receiving 10 mg O.D. for secondary prevention of cerebral
infarction. Unfortunately, coagulation function was not measured
before the onset of the event; it was measured only on the day of
the event when the patient was hospitalized (PT 11.4 s).
Bleeding events were observed in 25 patients (Table 3), where 23
of whom were over 70 years. Major bleeding events were observed in
four patients and consisted of two cases of intracranial hemorrhage,
one of hypermenorrhea, and one of upper gastrointestinal tractPe
ak
 P
T
CCr
(s)
(mL/min)
Fig. 2. Relationship between peak prothrombin time (PT) and creatinine clearance
(CCr). There was no correlation between peak PT and CCr (r = 0.012, p = 0.933) in
the overall group of patients examined for peak PT or in each of the three groups.
Table 2
Factors that prolonged peak prothrombin time.
Variable b p-Value
Female sex 0.370 0.011*
Log BNP 0.330 0.020*
Dose 0.328 0.026*
CCr 0.068 0.681
BNP, brain natriuretic peptide; CCr, creatinine clearance.
* p < 0.05.
Table 3
Characteristics of the patients who suffered bleeding events.
Patients with major
bleeding (n = 4)
Patients with non-major
bleeding (n = 21)
Patients without
bleeding events (n = 111)
Median days of administration period
(25th–75th percentile)
208 (166–272) 266 (27–496) 230 (69–292)
Median days to event
(25th–75th percentile)
198 (139–238) 47 (24–233) –
Age (years) 61.8  11.7 81.9  6.7 73.5  8.4
Sex, n
Male 1 10 75
Female 3 11 36
Body mass index 23.7  2.2 23.3  4.1 23.4  4.2
Body weight (kg) 63.2  9.9 56.2  12.8 59.9  11.8
Concurrent antiplatelet drugs, n 0 6 15
CHADS2 score 0.8  0.5 2.3  0.9 1.8  1.3
CCr (mL/min) 98.4  22.7 48.5  20.0 68.8  27.5
Dose and CCr, n
15 mg O.D., CCr 50 mL/min 4 5 49
10 mg O.D., CCr <50 mL/min 0 9 30
10 mg O.D., CCr 50 mL/min 0 7 32
CCr, creatinine clearance; O.D., once daily.
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patients had CHADS2scores 1. Minor bleeding events were observed
in 21 patients and included gastrointestinal bleeding, gingival
bleeding, nasal bleeding, macrohematuria, subcutaneous bleeding,
subcutaneous hematoma formation following cardiac catheteriza-
tion, hemosputum, and atypical genital bleeding.
Bleeding events and prothrombin time
Accurate coagulation function tests of peak PT were performed
in 15 of the 25 patients who suffered bleeding events. Among those
patients, the mean trough PT was 11.4  1.2 s and the mean peak PT
was 18.4  4.2 s. Receiver operating characteristic analysis showed
that the peak PT with 80% sensitivity for a bleeding event was 20.8 s.
We therefore allocated the patients to two groups, with peak PTs of
20 s or <20 s. Patients with peak PTs 20 s experienced signiﬁcant-
ly more bleeding events than those with peak PTs <20 s (62.5% vs.
22.7%, p = 0.022). The trough PTs were comparable between patients
with and without bleeding events.a
80.0 
60.0
SF
p = 0.006
p = 0.001
( g/mL)
Fig. 3. (a) Distribution of baseline, trough, and peak plasma soluble ﬁbrin (SF) levels
signiﬁcantly reduced compared to baseline values (1.92 mg/mL). (b) SF reduction ratio fr
Horizontal lines in boxes represent medians. Tops and bottoms of boxes indicate 75th a
minimum non-outliers, respectively. Circles indicate outliers above or below 1.5 timesSoluble ﬁbrin
In the 48-patient group, the median values for baseline, trough,
and peak SF were 1.92, 1.72, and 1.46 mg/mL, respectively
(Fig. 3a). The trough and peak SF levels were more signiﬁcantly
reduced than the baseline levels (p = 0.006 and p = 0.001,
respectively), especially in patients who had extremely high SF
levels at baseline. The ratios of SF reduction from baseline to peak
(peak SF/baseline SF) did not differ signiﬁcantly among patients
treated with 15 mg O.D. (CCr  50 mL/min) or 10 mg O.D.
(CCr < 50 mL/min or  50 mL/min) (Fig. 3b). There were no
signiﬁcant correlations between the peak PT and SF levels (data
not shown).
Coagulation function in patients treated with rivaroxaban without
previous anticoagulants
From among the 46 patients receiving rivaroxaban who had not
been treated with any previous anticoagulant, we were able to15mg O.D. 10mg O.D., 
CCr < 50mL/min
10mg O.D., 
CCr ≥ 50mL/min
b
p = 0.254
. The trough and peak SF levels (1.72 mg/mL and 1.46 mg/mL, respectively) were
om baseline to peak in each group according to creatinine clearance (CCr) and dose.
nd 25th percentile, respectively. Tops and bottoms of bars indicate maximum and
 the interquartile range from the 75th to the 25th percentile.
a b
p < 0.00 1
p < 0.00 1 p < 0.00 1
p = 0.00 3
PT SF
(s) (μg/mL)
Fig. 4. Changes in coagulation function from baseline to trough and peak in 29 patients receiving rivaroxaban without any previous anticoagulant therapy. (a) Prothrombin
time (PT) was signiﬁcantly prolonged at peak (16.9  3.2 s) compared to that observed at baseline (10.6  1.0 s) or at trough (10.9  0.9 s), whereas the trough value was
comparable to the baseline. (b) The baseline median soluble ﬁbrin (SF) level was 1.90 mg/mL. Following the initiation of treatment with rivaroxaban, the SF levels at both trough
(1.47 mg/mL) and peak (1.45 mg/mL) were signiﬁcantly reduced compared to those observed at baseline. Horizontal lines in boxes represent medians. Tops and bottoms of boxes
indicate 75th and 25th percentile, respectively. Tops and bottoms of bars indicate maximum and minimum non-outliers, respectively. Circles indicate outliers above or below
1.5 times the interquartile range from the 75th to the 25th percentile.
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signiﬁcantly prolonged at peak (16.9  3.2 s) than at baseline
(10.6  1.0 s, p < 0.001) or trough (10.9  0.9 s, p < 0.001) (Fig. 4a) in
these 29 patients. PT was not signiﬁcantly prolonged at trough than
the baseline value and the normal value used in our hospital
laboratory (10.9  0.2 s).
The SF level at baseline was distributed widely, with a median of
1.90 mg/mL (Fig. 4b) in these 29 patients. Following the initiation of
treatment with rivaroxaban, the SF levels at both trough and
peak were more signiﬁcantly reduced than at baseline (trough,
1.47 mg/mL; p = 0.003; peak, 1.45 mg/mL; p < 0.001) in these 29
patients. In addition, SF levels at trough and peak were comparable
(p = 0.314). Although a few patients displayed high SF levels at
baseline, their trough and peak SF levels dropped dramatically
within a short period after administration of the daily dose.
Discussion
Our main ﬁndings were as follows: (1) the mean peak PT was
17.1 s during rivaroxaban treatment. (2) Female sex, high BNP, and
high dose were the independent factors that affect prolonged peak
PT. (3) Patients who had peak PTs 20 s experienced signiﬁcantly
more bleeding events. (4) Among the patients receiving rivarox-
aban who had not received anticoagulants previously, the peak PT
was more signiﬁcantly prolonged than the trough and baseline PT
values, whereas the trough PT was similar to the baseline value and
to the normal value used in our hospital laboratory. (5) The SF
levels in patients receiving rivaroxaban without any previous
anticoagulant were signiﬁcantly reduced at both trough and peak
compared to baseline; however, there were no signiﬁcant
differences between the trough and peak SF levels.
Our results for the distribution of PT among Japanese patients
receiving rivaroxaban are similar to those previously reported [19].
As with other NOACs, rivaroxaban normally does not require
routine coagulation function testing. In routine medical practice,
the dose of rivaroxaban is determined according to the CCr and a
ﬁxed amount of the drug is administered [23,24]. However,
coagulation status must be evaluated in some patients on
anticoagulants, such as those with complications of heart failure,poor medication adherence, elevated plasma concentrations of the
drug, or hemorrhage, or undergoing emergency surgery.
PT is used widely to evaluate coagulation function in the clinical
setting. The results of anti-factor-Xa assay are correlated with the
concentration of rivaroxaban, but this assay cannot be easily
performed in all hospitals [15–18]. PT is a candidate measure for
evaluating whether coagulation function remains in the safe range in
each patient receiving rivaroxaban. In patients receiving rivarox-
aban, peak PTs are naturally prolonged. In our female patients, the
peak PT was marginally longer than in males. One of the reasons may
have been the fact that body surface area was signiﬁcantly smaller in
female patients than in males (males: 1.7 m2; females: 1.4 m2,
p < 0.001). The blood concentration of rivaroxaban could be higher
in patients with smaller body surface areas, thus leading to a more
prolonged PT value. One-third of rivaroxaban is excreted from the
kidneys unaltered. However, no correlation was seen between CCr
and peak PT; this may have been related to the fact that the CCr value
was used by the attending physician to adjust the dose.
We also did not ﬁnd any statistical relationship between peak
PT and age. This may have been due to CCr, which includes age as a
variable, and was used in determining the dose. Female sex, high
BNP, and high dose were independent factors affecting peak PT.
However, these results should be interpreted with caution because
of the small sample size.
Among patients whose coagulation function was measured
accurately, those with peak PTs 20 s experienced bleeding events
more frequently than did those with lower values. Although the
number of events was small, clinicians should be aware that
rivaroxaban patients with peak PTs 20 s may be at increased risk
of bleeding.
Elevated levels of SF are indicative of a high risk of deep vein
thrombosis [20–22]; patients with SF levels of <3 to <6 mg/mL are
less likely to develop deep vein thrombosis than those with higher
levels [21,22]. However, there have as yet been no reports of SF
levels in AF patients treated with NOACs. We used IATRO SF IITM to
measure SF levels, by which the manufacturer guaranteed the
linearity between 1.57 mg/mL and 7.9 mg/mL. Therefore, SF levels
above approximately 1.5 mg/mL are reliable. Here, we measured SF
levels at the initiation of therapy to evaluate the distribution of SF
Y. Nakano et al. / Journal of Cardiology 65 (2015) 185–190190levels in patients receiving rivaroxaban. We found that trough and
peak SF levels were substantially reduced after a few weeks of
therapy, unlike the reported SF levels in patients with deep vein
thrombosis [21,22]. This ﬁnding suggests that SF levels might be
suitable for estimating the efﬁcacy of rivaroxaban in patients at the
beginning of therapy.
Considerable numbers of patients with CCr 50 mL/min
received 10 mg O.D. in consideration of the presence of a previous
history of bleeding complications or concurrent use of antiplatelet
drugs. In fact, there will always be some at-risk patients with CCr
50 mL/min in whom the 10 mg O.D. dose should be considered. In
terms of SF levels and SF reduction ratio, we found no difference
between the three groups allocated by dose and CCr. However, care
should be taken to ensure that use of the lower dose is appropriate;
notably, the patient who suffered the one embolic event in this
study was on 10 mg O.D.
As a subanalysis, we examined a group of patients who were
receiving rivaroxaban and had not been treated previously with
anticoagulants. In this group, the trough SF level was signiﬁcantly
reduced compared to baseline, whereas the trough PT was not
prolonged and was similar to the baseline value. The Rocket AF
study demonstrated that the preventive effects of treatment with
rivaroxaban once daily with the evening meal on cerebral
infarction were non-inferior to those of warfarin in patients with
AF [10,14]. Our results suggest that administration of rivaroxaban
once daily in the morning could keep the SF level low, even at
trough; thus rivaroxaban might inhibit thrombus formation
sufﬁciently throughout the day.
Limitations
Our study was conducted at a single institution, and the
observations were made over a relatively short period and in a
limited number of subjects. Moreover, as PT measurements differ
depending on the reagent, our results cannot be simply compared
with those of other studies [17]. Although the peak time was deﬁned
as 3 h after drug administration, the time reﬂecting the actual peak
concentration of the drug may differ according to the individual.
Conclusion
Patients with non-valvular AF exhibited prolonged peak PTs
and reduced trough and peak SF levels after receiving rivaroxaban
compared to baseline. A prolonged peak PT (20 s) places patients
at increased risk of bleeding. Treating the patients with rivarox-
aban at a ﬁxed dose and without measuring their coagulation
function may expose them to the risk of hemorrhage in the future.
Measuring PT may help to screen for bleeding risk. PT and SF are
both valuable measures of coagulation status in patients receiving
rivaroxaban, regardless of prior anticoagulant history.
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